IDEAYA Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Announced a new Roche collaboration for a pan-RAS/PRMT5 combo in MTAP deletion pancreatic cancer. Darovasertib showed strong phase III results in uveal melanoma, with expedited FDA review underway. Multiple late-stage trials and data updates, including DLL3 ADC and KAT6/7 inhibitor, are expected in the second half of the year.
-
Darovasertib showed strong efficacy in uveal melanoma, with robust PFS and response rates, and NDA submission is underway with expedited review. ADC and bispecific programs are advancing, with large data sets and early efficacy signals expected this year. MTAP and KAT6/7 programs target high-need cancers with novel mechanisms.
-
Positive clinical results for darovasertib in uveal melanoma support expedited NDA filing, with detailed efficacy and safety data to be presented at ASCO. Pipeline progress includes upcoming DLL3 ADC data, expansion into adjuvant/neoadjuvant settings, and strategic focus on PRMT5, MAT2A, and KAT6/7 programs.
-
Focused on clinical distinction and procedural innovation, the company targets high-growth lateral surgery and imaging markets, achieving positive EBITDA and strong cash flow. Recent launches in robotics and international expansion support continued outsized growth and profitability.
-
Darovasertib plus crizotinib significantly improved progression-free survival and response rates in HLA-A2 negative metastatic uveal melanoma, with a favorable safety profile and early signs of overall survival benefit. The combination is poised to become a new standard, with ongoing studies in broader patient populations and earlier disease settings.
-
Darovasertib's phase III trial in metastatic uveal melanoma has completed enrollment, with top-line PFS data expected by end of March and NDA filing targeted for later this year. The pipeline includes promising ADC, MTAP, and KAT6/7 programs, with rapid neoadjuvant and combination studies underway.
-
Upcoming top-line data for darovasertib/crizotinib in metastatic uveal melanoma is expected by end of March, with strong prior efficacy signals. Multiple pipeline assets are advancing, including ADCs and MTAP-targeted therapies, with key readouts and regulatory filings planned over the next two years.
-
Revised summary: The presentation highlighted a strong oncology pipeline with nine clinical-stage assets, including darovasertib, nearing top-line results for metastatic uveal melanoma and FDA Breakthrough Therapy Designation. Strategies focus on ADC durability, MTAP deletion, and next-gen inhibitors, with pivotal studies and data readouts expected soon.
Fiscal Year 2025
-
Key clinical milestones are approaching for Darovasertib in uveal melanoma, with pivotal PFS data expected soon and multiple registrational trials underway. Promising results in DLL3 ADC and MTAP pathway programs highlight a robust pipeline, with several data updates and new combination strategies planned for next year.
-
Multiple late-stage trials are advancing, with darovasertib showing strong efficacy in uveal melanoma and new programs targeting MTAP deletion, DLL3, and bispecific ADCs. The pipeline spans high-value, underserved markets, with key data readouts and trial initiations expected over the next year.
-
Multiple clinical programs are advancing, with a pivotal PFS readout for darovasertib expected early next year. ADC and targeted therapy assets are progressing, with key data and regulatory milestones anticipated through 2026. Pricing and publication strategies are aligned with robust clinical results.
-
Major clinical progress was highlighted across uveal melanoma, MTAP, and DLL3 programs, with several assets nearing pivotal data and regulatory milestones. AI-driven drug discovery is accelerating pipeline advancement, and multiple early-stage assets are entering the clinic.
-
Multiple first-in-class oncology programs are advancing, with darovasertib showing strong efficacy in uveal melanoma and IDE849 demonstrating high response rates in small cell lung cancer. AI-driven discovery and strategic partnerships are accelerating pipeline growth and commercialization plans.
-
The conference highlighted major clinical milestones, including new data for Darovasertib and DLL3 ADC, a strategic Servier partnership, and a focus on AI-driven drug discovery. Top priorities are Darovasertib, MAT2A, and DLL3, with strong financial resources supporting growth.
-
Multiple late-stage clinical programs are advancing, with darovasertib targeting accelerated approval in metastatic uveal melanoma and several pipeline assets poised for key data readouts this year. Strong financials and a robust commercial build-out support a strategy focused on U.S. self-commercialization and leadership in targeted oncology.
-
Multiple clinical programs are advancing, with Darovasertib's pivotal trial targeting accelerated approval in HLA-A2 negative metastatic uveal melanoma by year-end. Significant market opportunity exists, and a strong cash position supports ongoing development, with several key data readouts and IND filings expected in the coming months.
-
Multiple pivotal data readouts for Darovasertib in uveal melanoma are expected by year-end 2025, with commercialization efforts focused on both HLA-A2 negative and positive populations. The pipeline is expanding with several assets in clinical and preclinical stages, and the company is leveraging global partnerships and regulatory designations to accelerate development.
-
Darovasertib is advancing in registrational trials for metastatic uveal melanoma, with strong efficacy signals and recent Breakthrough Therapy Designation in the neoadjuvant setting. Multiple pipeline assets, including Werner Helicase and DLL3 ADC, are set for key data readouts in 2024–2025.
-
A pivotal year is anticipated with darovasertib's potential approval in uveal melanoma and multiple key clinical readouts across a diversified oncology pipeline. Strategic focus includes advancing MTAP pathway assets, innovative combinations, and capital-efficient growth.
-
The conference highlighted a robust precision oncology pipeline with multiple late- and early-stage programs, emphasizing combination strategies to address tumor heterogeneity. Key milestones include upcoming data from darovasertib trials in uveal melanoma, IDE397 combinations, and new ADC assets, with several pivotal readouts expected in 2024.
-
Multiple first-in-class oncology programs are advancing, with key 2025 milestones including pivotal readouts for darovasertib in uveal melanoma and expansion of the clinical pipeline. Strategic business development complements a robust internal R&D engine, with a focus on rational combinations and regulatory progress.
Fiscal Year 2024
-
The event highlighted a robust precision oncology pipeline targeting tumor heterogeneity with multiple first-in-class agents, rational combinations, and innovative approaches. Key programs are advancing toward major 2025 milestones, supported by strong financials and strategic partnerships.
-
Darovasertib's pivotal trial in metastatic uveal melanoma is ahead of schedule, with a potential data readout for accelerated approval by late next year. Neoadjuvant strategies show strong eye and vision preservation, while the pipeline advances in MTAP-deleted tumors, PRMT5, Werner helicase, and PARG inhibitors.
-
The conference highlighted a robust pipeline focused on synthetic lethality, with promising clinical data for IDE397 and darovasertib, and innovative combination strategies targeting MTAP-deleted and uveal melanoma patients. Multiple first-in-class programs and key data readouts are expected in 2025.
-
The event detailed robust clinical progress in precision oncology, with strong enrollment in the lead uveal melanoma trial and new neoadjuvant and combination therapy programs advancing. Key commercial hires and a focused sales strategy support anticipated late 2026 launch plans.
-
Darovasertib demonstrated significant tumor shrinkage and eye preservation in phase 2 neoadjuvant uveal melanoma trials, with a favorable safety profile and strong potential to reduce radiation-related vision loss. The phase 3 registrational trial will use eye preservation and time to vision loss as primary endpoints, with interim analysis expected at two years.
-
Multiple first-in-class oncology programs are advancing, with darovasertib showing strong efficacy and safety in uveal melanoma and a pivotal FDA meeting set for Q3. MTAP deletion and DNA damage repair pathways are key strategic focuses, with several novel combinations and expansion candidates expected by year-end.
-
IDE397, a MAT2A inhibitor, showed promising phase II results in MTAP-deleted lung and urothelial cancers, with a 39% response rate, durable disease control, and a favorable safety profile. Preclinical and clinical data support both monotherapy and combination strategies, with a registration plan targeted for 2025.
-
The company is advancing a robust precision oncology pipeline, highlighted by strong clinical data in uveal melanoma and multiple first-in-class programs expected in the clinic by year-end. Strategic partnerships, innovative combination approaches, and a solid financial position support continued growth.
-
Darovosertib demonstrates strong tumor shrinkage and eye preservation in uveal melanoma, with pivotal phase II data and regulatory discussions expected in the second half of the year. The MAT2A/PRMT5 combination is advancing, and the pre-metastatic market opportunity is substantial.